// App-Quantinova.ai

106 : Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study.

Researchers

Presenter

  • Daniel J. George

Principal Investigators

  • Neal D. Shore

  • Fred Saad

  • Michael Cookson

  • Daniel Saltzstein

  • Ronald F. Tutrone

  • Hideyuki Akaza

  • Alberto Bossi

  • Elaine K. Wong

  • Bryan Selby

  • Xiaolin Fan

  • Jackie Walling

  • Bertrand Tombal

Medical Centers

  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • University of Oklahoma Health Sciences Center, Oklahoma City, OK

  • Urology San Antonio, San Antonio, TX

  • Chesapeake Urology, Towson, MD

  • The University of Tokyo, Tokyo, Japan

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Myovant Sciences, Brisbane, CA

  • Myovant Sciences, Brisbane, CA

  • Myovant Sciences, Brisbane, CA

  • Institut de Recherche Clinique, Universite Catholique de Louvain, Brussels, Belgium

Locations

  • United States

  • Canada

  • Japan

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • Leuprolide acetate

  • Docetaxel

  • relugolix

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03085095

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved